Last reviewed · How we verify

Recurrent Calcium Renal Calculi — Treatment Landscape & Competitive Intelligence

Recurrent Calcium Renal Calculi (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Recurrent Calcium Renal Calculi, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Aloprim ALLOPURINOL Casper Pharma Llc Xanthine Oxidase Inhibitor [EPC] Xanthine dehydrogenase/oxidase 1966-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Casper Pharma Llc · 1 drug in Recurrent Calcium Renal Calculi

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Recurrent Calcium Renal Calculi:

Cite this brief

Drug Landscape (2026). Recurrent Calcium Renal Calculi — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/recurrent-calcium-renal-calculi. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing